Dr. Winckler serves as Scientific Advisor to PrognomiQ. She is also Chief Scientific Officer for Droplet Biosciences. Before joining Droplet Biosciences, she was the Chief Scientific Officer at Glympse Bio, where she led the development of a novel protease activity diagnostic platform with programs in NASH and other disease areas. Prior to her time at Glympse Bio, Dr. Winckler was Executive Director at Novartis Institute for BioMedical Research, where she led Next Generation Diagnostics. Before joining Novartis, she was Director of the Genetic Analysis Platform at the Broad Institute. Dr. Winckler received a B.S. in Microbiology and Molecular Genetics from U from the University of California, Los Angeles, and a Ph.D. in Genetics from Harvard University.